{"id":55983,"date":"2023-04-19T09:05:09","date_gmt":"2023-04-19T07:05:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/"},"modified":"2023-04-19T09:05:09","modified_gmt":"2023-04-19T07:05:09","slug":"grunenthal-announces-pricing-of-e300-million-bond","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/","title":{"rendered":"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond"},"content":{"rendered":"
\n

AACHEN, Germany–(BUSINESS WIRE)–NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.<\/p>\n

\nGr\u00fcnenthal GmbH (the \u201cCompany\u201d) today announced the pricing of \u20ac300 million aggregate principal amount of 6.75% senior secured notes due 2030 (the \u201cNotes\u201d). The Notes will be issued at 100%. The Notes were offered outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d). In the United States, the Notes were offered only to qualified institutional buyers pursuant to Rule 144A under the Securities Act.<\/p>\n

\nThe Notes were rated \u2018BB+\u2019, \u2018BB-\u2018 and \u2018B1\u2019 by the three major independent credit rating agencies Fitch Ratings, Standard & Poor’s and Moody\u2019s Investors Service respectively.<\/p>\n

\nThis new financing will enhance Gr\u00fcnenthal\u2019s capital structure and its maturity profile. The Notes will provide additional flexibility for the company\u2019s strategy implementation and growth plans. The Company will use the proceeds from the Notes mainly to refinance its \u20ac200 million loan facility established in 2022 to partially fund the Nebido\u2122 acquisition, as well as to refinance its \u20ac75 million promissory notes.<\/p>\n

\nThis Notes issue follows on from Gr\u00fcnenthal successfully extending the maturities of its \u20ac500 million revolving credit facility earlier this year. The offering of the Notes is expected to close on 25 April 2023.<\/p>\n

\nThese materials are not an offer for sale of securities. The offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.<\/p>\n

\nThe Notes and the related guarantees have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the \u201cSecurities Act\u201d) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes and the related guarantees are being offered and sold (i) in the United States only to qualified institutional buyers in accordance with Rule 144A under the Securities Act and (ii) in \u201coffshore transactions\u201d to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act.<\/p>\n

\nThis communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom, (ii) persons who are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the \u201cOrder\u201d), (iii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or (iv) any persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or cause to be communicated (all such persons together being referred to as \u201crelevant persons\u201d). The investments to which this press release relates are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this press release or any of its contents.<\/p>\n

\nThe offer and sale of the Notes will be made pursuant to an exception under the Prospectus Regulation from the requirement to produce a prospectus for offers of securities. This press release does not constitute a prospectus within the meaning of the Prospectus Regulation or an offer to the public.<\/p>\n

\nManufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA.<\/p>\n

\nThe distribution of this press release into certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.<\/p>\n

\nForward-looking statements<\/p>\n

\nThis news release may include \u201cforward-looking statements\u201d within the meaning of the securities laws of certain applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this news release, including, without limitation, those regarding the Company\u2019s intentions, beliefs or current expectations concerning, among other things: the Company\u2019s future financial conditions and performance, results of operations and liquidity; the Company\u2019s strategy, plans, objectives, prospects, growth, goals and targets and future developments in the markets in which the Company participates or is seeking to participate. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms \u201canticipate\u201d, \u201cbelieve\u201d, \u201ccontinue\u201d, \u201congoing\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cpredict\u201d, \u201cproject\u201d, \u201ctarget\u201d, \u201cseek\u201d or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and that the Company\u2019s actual financial condition, results of operations and cash flows, and the development of the industry in which the Company operates, may differ materially.<\/p>\n

\nAbout Gr\u00fcnenthal<\/p>\n

\nGr\u00fcnenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better \u2013 and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.<\/p>\n

\nGr\u00fcnenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the U.S. Our products are available in approximately 100 countries. In 2022, Gr\u00fcnenthal employed around 4,400 people and achieved sales of \u20ac1.7 billion.<\/p>\n

\nMore information: www.grunenthal.com<\/a><\/p>\n

\nFollow us on:<\/p>\n

\nLinkedIn: Grunenthal Group<\/a><\/p>\n

\nInstagram: grunenthal<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nFlorian Dieckmann
\n
Tel:0241-569-2555
\n
Email:florian.dieckmann@grunenthal.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AACHEN, Germany–(BUSINESS WIRE)–NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Gr\u00fcnenthal GmbH (the \u201cCompany\u201d) today announced the pricing of \u20ac300 million aggregate principal amount of 6.75% … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55983","6":"format-standard","7":"category-industry"},"yoast_head":"\nGr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AACHEN, Germany–(BUSINESS WIRE)–NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Gr\u00fcnenthal GmbH (the \u201cCompany\u201d) today announced the pricing of \u20ac300 million aggregate principal amount of 6.75% ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-19T07:05:09+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/grunenthal-announces-pricing-of-e300-million-bond\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/grunenthal-announces-pricing-of-e300-million-bond\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond\",\"datePublished\":\"2023-04-19T07:05:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/grunenthal-announces-pricing-of-e300-million-bond\\\/\"},\"wordCount\":1113,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/grunenthal-announces-pricing-of-e300-million-bond\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/grunenthal-announces-pricing-of-e300-million-bond\\\/\",\"name\":\"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-04-19T07:05:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/grunenthal-announces-pricing-of-e300-million-bond\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/grunenthal-announces-pricing-of-e300-million-bond\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/grunenthal-announces-pricing-of-e300-million-bond\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/","og_locale":"en_US","og_type":"article","og_title":"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond - Pharma Trend","og_description":"AACHEN, Germany–(BUSINESS WIRE)–NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Gr\u00fcnenthal GmbH (the \u201cCompany\u201d) today announced the pricing of \u20ac300 million aggregate principal amount of 6.75% ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-19T07:05:09+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond","datePublished":"2023-04-19T07:05:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/"},"wordCount":1113,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/","url":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/","name":"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-04-19T07:05:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/grunenthal-announces-pricing-of-e300-million-bond\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Gr\u00fcnenthal Announces Pricing of \u20ac300 Million Bond"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55983"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55983\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}